Alan Skarbnik, MD
Dr Alan Skarbnik serves as the Director of the Lymphoma and CLL Program and Director of the Immune Effector Cell and Experimental Therapeutics Program at the Novant Health Cancer Institute in North Carolina. He is also a Clinical Assistant Professor at the University of North Carolina School of Medicine.
Dr Skarbnik is a native from Brazil, where he graduated from medical school. He moved to New York City, having completed his residency at St. Luke's Roosevelt Hospital Center. He completed a Hematology/Oncology fellowship at the Fox Chase Cancer Center in Philadelphia and a Hematopoietic Stem Cell Transplantation fellowship at the City of Hope National Medical Center in California.
Dr Skarbnik has participated and published on multiple clinical trials in the fields of Lymphoma, CLL, CAR-T cell therapy and Transplantation.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbvieDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ADC TherapeuticsDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:CelgeneDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BeigeneDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenentechDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Kite PharmaDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:LillyDate added:04/04/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenDate added:04/04/2024